These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38627816)

  • 1. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
    Zhao Y; Yu Y; Li X; Guo A
    J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nu├▒ez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of p300 in paclitaxel-resistant TNBC: implications for cell proliferation via the PCK1/AMPK axis.
    Zhao PW; Cui JX; Wang XM
    Pharmacogenomics J; 2024 Feb; 24(2):5. PubMed ID: 38378770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PD-L1 Aptamer Selected by Loss-Gain Cell-SELEX Conjugated with Paclitaxel for Treating Triple-Negative Breast Cancer.
    Wu X; Li F; Li Y; Yu Y; Liang C; Zhang B; Zhao C; Lu A; Zhang G
    Med Sci Monit; 2020 Jun; 26():e925583. PubMed ID: 32574155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-2 Up-Regulation Mediates Taxane Resistance Downstream of APC Loss.
    Wise AR; Maloney S; Hering A; Zabala S; Richmond GE; VanKlompenberg MK; Nair MT; Prosperi JR
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
    Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
    Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFSF13 upregulation confers chemotherapeutic resistance via triggering autophagy initiation in triple-negative breast cancer.
    Lin HY; Kuei CH; Lee HH; Lin CH; Chen YL; Chen CL; Lin YF
    J Mol Med (Berl); 2020 Sep; 98(9):1255-1267. PubMed ID: 32671412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA PRKCQ-AS1 regulates paclitaxel resistance in triple-negative breast cancer cells through miR-361-5p/PIK3C3 mediated autophagy.
    Zheng S; Fu W; Huang Q; Zhou J; Lu K; Gu J; Ma R; Guo G
    Clin Exp Pharmacol Physiol; 2023 Jun; 50(6):431-442. PubMed ID: 36732923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macitentan improves antitumor immune responses by inhibiting the secretion of tumor-derived extracellular vesicle PD-L1.
    Lee CH; Bae JH; Choe EJ; Park JM; Park SS; Cho HJ; Song BJ; Baek MC
    Theranostics; 2022; 12(5):1971-1987. PubMed ID: 35265193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
    Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
    Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/PD-L1 signaling.
    Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
    J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy.
    Zheng B; Qian F; Wang X; Wang Y; Zhou B; Fang L
    J Exp Clin Cancer Res; 2024 Jun; 43(1):177. PubMed ID: 38926803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
    Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
    J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
    Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
    Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
    Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with┬ábreast cancer: TNBC versus TPBC.
    Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
    Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA.
    Yang X; Zhao L; Pei J; Wang Z; Zhang J; Wang B
    Breast Cancer Res Treat; 2020 Aug; 183(1):71-82. PubMed ID: 32601971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of RBMS3 suppresses PD-L1 and enhances antitumor immune activities and therapeutic effects of auranofin against triple-negative breast cancer.
    Zhou Y; Liang Z; Xia Y; Li S; Liang J; Hu Z; Tang C; Zhao Q; Gong Q; Ouyang Y
    Chem Biol Interact; 2023 Jan; 369():110260. PubMed ID: 36414028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.